IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412
CPKC412A2218
Phase 2 small_molecule active
Quick answer
IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412 for untreated FLT3-mutated Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- untreated FLT3-mutated Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active